홈 › 신장암 (신세포암) › 콜로라도
콜로라도의 신장암 (신세포암) 임상 시험
신장암 (신세포암) 관련 연구 15개가 콜로라도 내 여러 지역에서 참여자를 모집하고 있습니다.
콜로라도의 도시
공식 연구 텍스트(영어)
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- University of Colorado Anschutz Medical Campus, Aurora
- Rocky Mountain Cancer Centers, LLP, Lone Tree
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06234605Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Rocky Mountain Regional VA Medical Center, Aurora
- UCHealth University of Colorado Hospital, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- 외 15개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #87, Littleton
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT05176483DESTINY-PANTUMOUR04
- Research Site, Boulder
피험자 모집 중관찰 연구
18세 ~ 130세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07124000Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- UCHealth University of Colorado Hospital, Aurora
- UCHealth - Cherry Creek, Denver
- Poudre Valley Hospital, Fort Collins
- 외 5개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT05327686Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Rocky Mountain Cancer Centers,LLP, Aurora
- Clinical and Translational Research Center(CTRC), Aurora
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora
- 외 8개
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07227415ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Colorado, Aurora
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT05059444Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- UCHealth University of Colorado Hospital, Aurora
- UCHealth Memorial Hospital Central, Colorado Springs
- Memorial Hospital North, Colorado Springs
- 외 7개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT06661720Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Sarah Cannon Research Institute - Denver DDU, Denver
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 27. 업데이트됨 · NCT06582017Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
- University of Colorado Anschutz Medical Campus, Aurora
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 21. 업데이트됨 · NCT06432036A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Sarah Cannon Research Institute (SCRI), Denver
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 7. 9. 업데이트됨 · NCT03972657KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Sarah Cannon Research Institute at HealthONE, Denver
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 8. 업데이트됨 · NCT06026410A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- University of Colorado Cancer Center, Aurora
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 4. 13. 업데이트됨 · NCT06362369Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
- University of Colorado Cancer Center, Aurora
- Hilands Ranch Hospital, Highlands Ranch
- Lone Tree Medical Center, Lone Tree
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 13. 업데이트됨 · NCT05969496Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Sarah Cannon Research Institute at HealthONE, Denver
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2024. 11. 15. 업데이트됨 · NCT04787042ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.